These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 38384458)

  • 21. Targeting NKG2D ligands in glioblastoma with a bispecific T-cell engager is augmented with conventional therapy and enhances oncolytic virotherapy of glioma stem-like cells.
    Baugh R; Khalique H; Page E; Lei-Rossmann J; Wan PK; Johanssen T; Ebner D; Ansorge O; Seymour LW
    J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38724464
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients.
    Agnihotri S; Gajadhar AS; Ternamian C; Gorlia T; Diefes KL; Mischel PS; Kelly J; McGown G; Thorncroft M; Carlson BL; Sarkaria JN; Margison GP; Aldape K; Hawkins C; Hegi M; Guha A
    J Clin Invest; 2012 Jan; 122(1):253-66. PubMed ID: 22156195
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Radiosensitizing effects of temozolomide observed in vivo only in a subset of O6-methylguanine-DNA methyltransferase methylated glioblastoma multiforme xenografts.
    Carlson BL; Grogan PT; Mladek AC; Schroeder MA; Kitange GJ; Decker PA; Giannini C; Wu W; Ballman KA; James CD; Sarkaria JN
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):212-9. PubMed ID: 19695438
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic significance of O6-methylguanine-DNA methyltransferase protein expression in patients with recurrent glioblastoma treated with temozolomide.
    Nagane M; Kobayashi K; Ohnishi A; Shimizu S; Shiokawa Y
    Jpn J Clin Oncol; 2007 Dec; 37(12):897-906. PubMed ID: 18156172
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma.
    Jiapaer S; Furuta T; Tanaka S; Kitabayashi T; Nakada M
    Neurol Med Chir (Tokyo); 2018 Oct; 58(10):405-421. PubMed ID: 30249919
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of lomeguatrib-temozolomide combination on MGMT promoter methylation and expression in primary glioblastoma tumor cells.
    Taspinar M; Ilgaz S; Ozdemir M; Ozkan T; Oztuna D; Canpinar H; Rey JA; Sunguroğlu A; Castresana JS; Ugur HC
    Tumour Biol; 2013 Jun; 34(3):1935-47. PubMed ID: 23519841
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recycling of SLC38A1 to the plasma membrane by DSCR3 promotes acquired temozolomide resistance in glioblastoma.
    Lin R; Xu Y; Xie S; Zhang Y; Wang H; Yi GZ; Huang G; Ni B; Song H; Wang Z; Qi ST; Liu Y
    J Neurooncol; 2022 Mar; 157(1):15-26. PubMed ID: 35187626
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NKG2D ligands in glioma stem-like cells: expression in situ and in vitro.
    Flüh C; Chitadze G; Adamski V; Hattermann K; Synowitz M; Kabelitz D; Held-Feindt J
    Histochem Cell Biol; 2018 Mar; 149(3):219-233. PubMed ID: 29356965
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-glioma therapy with temozolomide and status of the DNA-repair gene MGMT.
    Fukushima T; Takeshima H; Kataoka H
    Anticancer Res; 2009 Nov; 29(11):4845-54. PubMed ID: 20032445
    [TBL] [Abstract][Full Text] [Related]  

  • 30. O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells.
    Hermisson M; Klumpp A; Wick W; Wischhusen J; Nagel G; Roos W; Kaina B; Weller M
    J Neurochem; 2006 Feb; 96(3):766-76. PubMed ID: 16405512
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of aberrant p53 function on temozolomide sensitivity of glioma cell lines and brain tumor initiating cells from glioblastoma.
    Blough MD; Beauchamp DC; Westgate MR; Kelly JJ; Cairncross JG
    J Neurooncol; 2011 Mar; 102(1):1-7. PubMed ID: 20593219
    [TBL] [Abstract][Full Text] [Related]  

  • 32. NKG2D- and T-cell receptor-dependent lysis of malignant glioma cell lines by human γδ T cells: Modulation by temozolomide and A disintegrin and metalloproteases 10 and 17 inhibitors.
    Chitadze G; Lettau M; Luecke S; Wang T; Janssen O; Fürst D; Mytilineos J; Wesch D; Oberg HH; Held-Feindt J; Kabelitz D
    Oncoimmunology; 2016 Apr; 5(4):e1093276. PubMed ID: 27141377
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Involvement of N-methylpurine DNA glycosylase in resistance to temozolomide in patient-derived glioma cells.
    Serrano-Heras G; Castro-Robles B; Romero-Sánchez CM; Carrión B; Barbella-Aponte R; Sandoval H; Segura T
    Sci Rep; 2020 Dec; 10(1):22185. PubMed ID: 33335215
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BET protein inhibition sensitizes glioblastoma cells to temozolomide treatment by attenuating MGMT expression.
    Tancredi A; Gusyatiner O; Bady P; Buri MC; Lomazzi R; Chiesi D; Messerer M; Hegi ME
    Cell Death Dis; 2022 Dec; 13(12):1037. PubMed ID: 36513631
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Circadian regulation of MGMT expression and promoter methylation underlies daily rhythms in TMZ sensitivity in glioblastoma.
    Gonzalez-Aponte MF; Damato AR; Trebucq LL; Simon T; Cárdenas-García SP; Cho K; Patti GJ; Golombek DA; Chiesa JJ; Rubin JB; Herzog ED
    J Neurooncol; 2024 Feb; 166(3):419-430. PubMed ID: 38277015
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Methionine restriction of glioma does not induce MGMT and greatly improves temozolomide efficacy in an orthotopic nude-mouse model: A potential curable approach to a clinically-incurable disease.
    Kubota Y; Aoki Y; Masaki N; Obara K; Hamada K; Han Q; Bouvet M; Tsunoda T; Hoffman RM
    Biochem Biophys Res Commun; 2024 Feb; 695():149418. PubMed ID: 38176171
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transcriptional control of O
    Happold C; Stojcheva N; Silginer M; Weiss T; Roth P; Reifenberger G; Weller M
    J Neurochem; 2018 Mar; 144(6):780-790. PubMed ID: 29480969
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exploring the Mechanism of Adjuvant Treatment of Glioblastoma Using Temozolomide and Metformin.
    Feng SW; Chang PC; Chen HY; Hueng DY; Li YF; Huang SM
    Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897747
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The nanoprodrug of polytemozolomide combines with MGMT siRNA to enhance the effect of temozolomide in glioma.
    Xu H; Zhang Y; Li L; Ren Y; Qian F; Wang L; Ma H; Quan A; Liu H; Yu R
    Drug Deliv; 2023 Dec; 30(1):1-13. PubMed ID: 36579448
    [TBL] [Abstract][Full Text] [Related]  

  • 40. dCas9/CRISPR-based methylation of O-6-methylguanine-DNA methyltransferase enhances chemosensitivity to temozolomide in malignant glioma.
    Zapanta Rinonos S; Li T; Pianka ST; Prins TJ; Eldred BSC; Kevan BM; Liau LM; Nghiemphu PL; Cloughesy TF; Lai A
    J Neurooncol; 2024 Jan; 166(1):129-142. PubMed ID: 38224404
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.